Form PTO-1390-MOD U. S. (REV 10-96)	Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER LA/3-333 1 2. A								
TRANSMITTAL LETTER TO 1	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
DESIGNATED/ELECTED O	Not Yet Assigned									
CONCERNING A FILING UNINTERNATIONAL APPLICATION NO.	NDER 35 U.S.C. 371 INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
PCT/EP04/008994	12 August 2003 (12.08.03)									
TITLE OF INVENTION TOPICAL COMPOSTION COMPRISING TERBINAFINE ADN HYDROCORTISONE										
APPLICANT(S) FOR DO/EO/US										
LARNIER ET AL. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
 This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) 										
c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). a. are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35										
U.S.C. 371(c)(5)).		:								
Items 11. to 16. below concern document	(s) or information included.									
11. An Information Disclosure Statemen	t under 37 CFR 1.97 and 1.98.									
12. An assignment document for recording included.	ng. A separate cover sheet in comp	pliance with 37 CFR 3.28 and 3.31 is								
13. A FIRST preliminary amendment.A SECOND or SUBSEQUENT preliminary	ninary amendment.									
14. An Application Data Sheet under 37	CFR 1.76.									
15. A substitute specification.										
16. A change of power of attorney and/o	or address letter.									
17. A computer-readable form of the sec 1.825.	quence listing in accordance with PC	CT Rule 13ter.2 and 37 CFR 1.821-								
18. A second copy of the published Inter	rnational Application under 35 U.S.C	C. 154(d)(4).								
19. A second copy of the English langua	age translation of the International a	oplication under 35 U.S.C. 154(d)(4).								
20. Other items or information: Unexect	uted Declaration and Post Card.	·								

MAPZURGGUNINATO 02 FEB 2006

Not Yet Assign	ed n	<u>a</u> aa		Γ/EP04/008994			LA/3-3332	3321A			
	The following fees are submitted:					CALCULATIONS PTO USE					
								ONLY			
21. 🛭 Basi	☒ Basic national fee. \$300										
22. Examination Fee											
If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$											
. All other situations											
23. Search fee											
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international											
application to the USPTO as an International Searching Authority \$ If International Search Report was prepared and provided to the Office \$											
All other situations											
TOTAL OF 21, 22 AND 23 =						\$	1,000				
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer											
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra	sheets		ach additional 50 or d up to a whole nur		F	RATE				
9 - 100 =		/50 =		0		X \$	250	\$			
Surcharge of \$1	30 for fu	rnishina the	oath of declar	ration later than	□ 30			\$		•	
Surcharge of \$130 for furnishing the oath of declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						Ψ					
CLAIMS			ER FILED	NUMBER EXT		RA C					
Total claims Independent cla	ime	9 2	- 20 =	0		X \$ X \$	50 200	\$			
MULTIPLE DEF						+ \$	360	\$			
TOTAL OF ABOVE CALCULATIONS =							\$	1,000			
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).						\$					
SUBTOTAL =						\$	1,000				
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$					
	•				TOTAL	NATION	AL FEE =	\$	1,000		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied											
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +					\$	1,000					
TOTAL FEES ENCLOSED =							mount to	\$			
							refunded				
								charged	\$		
a. A chec	k in the	amount of \$		to cover the ab	ove fees is	enclosed	•				
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,000 to cover the above fees. A duplicate copy of this form is enclosed.											
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
			•		Michael					 -	
Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 35,240											
Corporate Intellectual Property Reg. No. 35,240 One Health Plaza, Building 104 (862) 778-7879								,			
East Hanover, NJ 07936-1080											